Literature DB >> 33964477

Clinical Presentation, Diagnostic Findings, and Long-term Survival Time in 182 Dogs With Meningoencephalitis of Unknown Origin From Central Europe That Were Administered Glucocorticosteroid Monotherapy.

Tereza Kosinová Paušová1, Ales Tomek2, Petr Šrenk3, Silvie Belašková4.   

Abstract

Canine non-infectious inflammatory meningoencephalomyelitis is termed meningoencephalomyelitis of unknown origin (MUO) and may affect dogs of every breed at any age. Treatment with immunosuppressive medication, the survival time based on MRI, and cerebrospinal fluid (CSF) findings has been widely reported; however, these studies only included a small number of patients, or they are summaries from the literature. Therefore, the aim of this study was to compare the clinical presentation, diagnostic findings, treatment protocol and long-term survival time in many dogs diagnosed with MUO in one clinic with previously published studies. One hundred eighty-two dogs met the inclusion criteria. Age, sex, duration of clinical signs before diagnosis, presence of neurological signs, MRI and CSF analysis were similar to those in previous reports. Our study revealed that dogs with a brainstem lesion have a 60% lower chance of death before 1 year than dogs with multifocal brain lesions. A total of 55.56% of treated dogs survived for more than 1 year, and 10.55% survived for more than 5 years since diagnosis. The median survival time for all dogs was 540 days. Our findings support glucocorticosteroid monotherapy as a viable treatment option for dogs with MUO.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Meningoencephalomyelitis of unknown origin (MUO); central nervous system; dog; glucocorticosteroids; immunosuppression; survival

Year:  2021        PMID: 33964477     DOI: 10.1016/j.tcam.2021.100539

Source DB:  PubMed          Journal:  Top Companion Anim Med        ISSN: 1946-9837


  5 in total

1.  Treatment With Cytarabine at Initiation of Therapy With Cyclosporine and Glucocorticoids for Dogs With Meningoencephalomyelitis of Unknown Origin Is Not Associated With Improved Outcomes.

Authors:  Renee Barber; Lauren Downey Koos
Journal:  Front Vet Sci       Date:  2022-06-10

2.  Case Report: Anti-GABA A Receptor Encephalitis in a Dog.

Authors:  Enrice I Huenerfauth; Christian G Bien; Corinna Bien; Holger A Volk; Nina Meyerhoff
Journal:  Front Vet Sci       Date:  2022-06-23

3.  Detection of blood-brain barrier dysfunction using advanced imaging methods to predict seizures in dogs with meningoencephalitis of unknown origin.

Authors:  Erez Hanael; Shelly Baruch; Orit Chai; Zohar Nir; Kira Rapoport; Marco Ruggeri; Itzhak Eizenberg; Dana Peery; Alon Friedman; Merav H Shamir
Journal:  J Vet Intern Med       Date:  2022-03-14       Impact factor: 3.333

4.  Magnetic resonance imaging highlights the meningeal involvement in steroid responsive meningitis-arteritis and suggests the inflammation of the surrounding tissues (70 cases).

Authors:  Carlotta Remelli; Alba Martello; Alessia Valentini; Barbara Contiero; Marco Bernardini
Journal:  Front Vet Sci       Date:  2022-08-19

5.  Evaluation of the blood neutrophil-to-lymphocyte ratio as a biomarker for meningoencephalitis of unknown etiology in dogs.

Authors:  Jooyoung Park; Dohee Lee; Taesik Yun; Yoonhoi Koo; Yeon Chae; Hakhyun Kim; Mhan-Pyo Yang; Byeong-Teck Kang
Journal:  J Vet Intern Med       Date:  2022-08-05       Impact factor: 3.175

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.